In the past week, APVO stock has gone down by -12.76%, with a monthly decline of -32.72% and a quarterly plunge of -91.56%. The volatility ratio for the week is 40.88%, and the volatility levels for the last 30 days are 17.48% for Aptevo Therapeutics Inc The simple moving average for the past 20 days is -11.12% for APVO’s stock, with a -95.60% simple moving average for the past 200 days.
Is It Worth Investing in Aptevo Therapeutics Inc (NASDAQ: APVO) Right Now?
Company’s 36-month beta value is 5.73.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The average trading volume of APVO on June 23, 2025 was 2.31M shares.
APVO) stock’s latest price update
Aptevo Therapeutics Inc (NASDAQ: APVO)’s stock price has soared by 3225695 in relation to previous closing price of 5.13. Nevertheless, the company has seen a loss of -12.76% in its stock price over the last five trading days. accessnewswire.com reported 2025-06-20 that SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previously announced offering of (i) 2,465,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 12,325,000 shares of its common stock (the “Common Warrants”) at a purchase price of $3.25 per share and associated Common Warrants in a registered direct offering priced at-the-market under Nasdaq rules. Each share of common stock is being offered together with five Common Warrants, each to purchase one share of common stock.
Analysts’ Opinion of APVO
Piper Jaffray, on the other hand, stated in their research note that they expect to see APVO reach a price target of $6. The rating they have provided for APVO stocks is “Overweight” according to the report published on October 05th, 2017.
APVO Trading at -53.00% from the 50-Day Moving Average
After a stumble in the market that brought APVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.14% of loss for the given period.
Stock Fundamentals for APVO
The total capital return value is set at -8.17. Equity return is now at value -1023.93, with -182.54 for asset returns.
Based on Aptevo Therapeutics Inc (APVO), the company’s capital structure generated 1.5 points at debt to capital in total, while cash flow to debt ratio is standing at -5.36.
Currently, EBITDA for the company is -23.78 million with net debt to EBITDA at -0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.67.
Conclusion
In a nutshell, Aptevo Therapeutics Inc (APVO) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts.
